GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck

GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.